Potential COVID-19 vaccine by Zydus Cadila gets DCGI nod for human clinical trials

The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI.

Updated - July 03, 2020 12:06 pm IST

Published - July 03, 2020 11:13 am IST - New Delhi

File photo for representational purpose only.

File photo for representational purpose only.

A potential COVID-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd. has got the nod from the Drugs Controller General of India (DCGI) for human clinical trials, according to a government source.

The approval process was fast-tracked following recommendation by the subject expert committee on COVID-19, considering the emergency and unmet medical need during the pandemic.

“DCGI Dr. V.G. Somani has given approval for the phase I and II clinical trials (on humans) of the potential novel coronavirus vaccine developed by Zydus Cadila Healthcare Ltd. on Thursday after its animal studies were found to be successful,” an official source in the know of the developments told PTI.

The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI, in which the vaccine candidate was found to be successful with respect to safety and immunogenicity, the source said.

The company is likely to start enrolment of subjects soon.

“The phase I and II trials will take around three months to be completed,” the source said.

The country’s ‘first’ indigenous COVID-19 vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology (NIV), had recently got the nod for human clinical trials from the DCGI.

India’s COVID-19 tally rose to 6,04,641 on Thursday with a single-day increase of 19,148 cases, just five days after it crossed the five-lakh mark, while the death toll rose to 17,834 with 434 new fatalities, according to the Union Health Ministry.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.